Literature DB >> 31535749

Melatonin promotes osteoblastic differentiation and regulates PDGF/AKT signaling pathway.

Guiling Zhu1, Bin Ma2, Penghong Dong1, Junjun Shang1, Xiaochuan Gu3, Ying Zi4.   

Abstract

Melatonin has been reported to participate in bone metabolism in recent studies. However, the underlying mechanism in melatonin-mediated osteoblastic differentiation remains largely unknown. The aim of this study is to investigate the role of melatonin in osteoblastic differentiation. In the present study, additional melatonin significantly promoted osteoblastic differentiation of MC3T3-E1 cells as evidenced by increased messenger RNA (mRNA) levels of osteogenic markers, alkaline phosphatase (ALP), collagen type I α1 chain, osteocalcin, and runt-related transcription factor 2 (Runx2). It was noteworthy that the expression level of platelet-derived growth factor subunit B (PDGFB) and content of its homodimer PDGF-BB were remarkably increased after melatonin administration. Moreover, the mRNA levels of phosphorylated PDGFRβ (PDGF receptor β) and Akt, a serine/threonine-specific protein kinase, were significantly upregulated in melatonin-treated MC3T3-E1 cells determined by a real-time polymerase chain reaction. Besides, by performing alizarin red staining, osteoblastic differentiation of MC3T3-E1 cells was conspicuously promoted by melatonin, which could be partially attenuated by crenolanib, a PDGFR inhibitor. Similarly, results from immunofluorescence and western blot assay showed that melatonin-induced upregulation of Runx2 and phosphorylated Akt was suppressed by crenolanib. Akt inhibition by MK-2206 also suppressed osteoblastic differentiation. Furthermore, by in vivo assay, additional melatonin promoted osteoblastic differentiation in mice with femoral fracture, and obvious callus formation was observed in melatonin-treated mice 5 weeks after fracture. Melatonin supplement also inhibited osteoclastic differentiation in mice. All statistical analysis was performed using GraphPad Prism and a P < 0.05 was deemed to be significant. To summarize, we demonstrate that melatonin promotes osteoblastic differentiation in MC3T3-E1 cells and enhances fracture healing in mouse femoral fracture model and regulates PDGF/AKT signaling pathway.
© 2019 International Federation for Cell Biology.

Entities:  

Keywords:  AKT signaling; PDGF signaling; bone resorption; fracture healing; melatonin; osteoblastic differentiation

Year:  2019        PMID: 31535749     DOI: 10.1002/cbin.11240

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  5 in total

1.  Insight into the roles of melatonin in bone tissue and bone‑related diseases (Review).

Authors:  Xiaofeng Lu; Shaoling Yu; Guangjin Chen; Wenhao Zheng; Jinfeng Peng; Xiaofei Huang; Lili Chen
Journal:  Int J Mol Med       Date:  2021-03-24       Impact factor: 4.101

2.  Melatonin enhances osteogenic differentiation of dental pulp mesenchymal stem cells by regulating MAPK pathways and promotes the efficiency of bone regeneration in calvarial bone defects.

Authors:  Ya-Hui Chan; Kuo-Ning Ho; Yu-Chieh Lee; Meng-Jung Chou; Wei-Zhen Lew; Haw-Ming Huang; Pin-Chuang Lai; Sheng-Wei Feng
Journal:  Stem Cell Res Ther       Date:  2022-02-19       Impact factor: 6.832

Review 3.  Hormone and implant osseointegration: Elaboration of the relationship among function, preclinical, and clinical practice.

Authors:  Ming Yi; Ying Yin; Jiwei Sun; Zeying Wang; Qingming Tang; Cheng Yang
Journal:  Front Mol Biosci       Date:  2022-09-15

4.  Melatonin Promotes Antler Growth by Accelerating MT1-Mediated Mesenchymal Cell Differentiation and Inhibiting VEGF-Induced Degeneration of Chondrocytes.

Authors:  Xuyang Sun; Xiaoying Gu; Keke Li; Mengqi Li; Jingna Peng; Xinxin Zhang; Liguo Yang; Jiajun Xiong
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

5.  Melatonin Accelerates Osteoporotic Bone Defect Repair by Promoting Osteogenesis-Angiogenesis Coupling.

Authors:  Sheng Zheng; Chunhao Zhou; Han Yang; Junhua Li; Ziyu Feng; Liqing Liao; Yikai Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.